A Phase 2 interventional study of AG-013736 (axitinib) in Kidney Neoplasms and Carcinoma, Renal Cell, sponsored by Pfizer. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-31.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.
Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 13th largest by enrollment, is the only one that started in 2006, is one of 29 in phase 2, and was the 1st registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
Browse Carcinoma, Renal Cell studies →11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
Stephanie Berg · Sites in United States
Ages 18+
Tianjin Medical University Second Hospital · Sites in China
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–80
By country, each count listing its studies:
Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 31 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is above the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 41 interventional studies. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 41 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
80 studies in Carcinoma, Renal Cell by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 74 finished, 54 (73%) have results posted.
Among the 80 studies in Carcinoma, Renal Cell by Pfizer, this one is the 20th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2006, is one of 11 in phase 2, and was the 11th registered.
Pfizer’s Carcinoma, Renal Cell studies by the year they started, since 2002.
2 of the studies testing axitinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07159191Peking Union Medical College HospitalEnvafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | 2027-02-20 |
| NCT07123090Stephanie BergA Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies testing axitinib in Carcinoma, Renal Cell, from their registry updates:
Among Pfizer’s 80 in Carcinoma, Renal Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
This study's enrollment of 62 is above the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.
Browse Carcinoma, Renal Cell studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Carcinoma, Renal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity
Drug: AG-013736 (axitinib)
AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.
Percentage of Participants With Objective Response (OR)
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of responses. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.
Time frame: Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 152 weeks
Progression-free Survival (PFS)
Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
Time frame: Baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 152 weeks
Duration of Response (DR)
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 152 weeks
Overall Survival (OS)
Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.
Time frame: Baseline to death due to any cause or at least 1 year after the first dose for the last participant
Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index for Disease Cancer Related Symptoms (FKSI-DRS) Score
FKSI-DRS is a subset of FKSI which is a questionnaire for FACT -Kidney Symptom Index used to assess Quality of Life (QoL)/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions and the FKSI-DRS consisted of 9 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI-DRS ranged between 0-36. Since the questions could be reversed coded, as appropriate, before calculating FKSI-DRS, 0 and 36 could be considered the worst and best health states based on the 9 questions comprising FKSI-DRS.
Time frame: Baseline (Day 1 of Cycle 1), Day 1 of all subsequent cycles up to Cycle 38 and follow up (28 days after last dose)
Population Pharmacokinetics of Axitinib (AG-013736)
Data for this outcome measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 1 (Pre-dose), Day 29, Day 57 and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks
Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index (FKSI) Score
FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms.
Time frame: Baseline (Day 1 of Cycle 1), Day 1 of all subsequent cycles up to Cycle 38 and follow up (28 days after last dose)
Correlation of Area Under the Concentration-time Curve at Steady State (AUCss) With Confirmed Partial Response (PR)
AUCss: pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods, computed as each participant's average total daily dose (accounting for dose reductions and any recorded missed doses) divided by population estimated posthoc individual apparent clearance (CL/F), i.e., AUCss = Daily Dose/(CL/F), where F refers to the oral bioavailability, and CL refers to the systemic clearance. PR: responses with at least 30% decrease in sum of longest dimensions of target lesions using baseline (pre-treatment) sum of longest dimensions as reference. Logistic regression with general linear model was applied to data of PR using AUCss; PR was correlated with AUCss as fold increase in odds of PR with increase in AUCss. Fold increase was calculated as exponent of product of logistic regression slope coefficient and unit change of AUCss.
Time frame: Day 1 (Pre-dose), Day 29 and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks
Relationship of Area Under the Concentration-time Curve at Steady State (AUCss) With Progression-free Survival (PFS)
AUCss is a pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods. PFS is median time from first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. Relationship of PFS versus AUCss was determined as median PFS in participants with high AUCss \[AUCss greater than or equal to (\>=) median AUCss\] or low AUCss \[AUCss less than (\<) median AUCss\].
Time frame: Day 1 (Pre-dose), Day 29, and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks
Relationship of Area Under the Concentration-time Curve at Steady State (AUCss) With Overall Survival (OS)
AUCss is a pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods. OS is time in weeks from the start of study treatment to date of death due to any cause. Relationship of OS versus AUCss was determined as median OS in participants with high AUCss \[AUCss \>= median AUCss\] or low AUCss \[AUCss \< median AUCss\].
Time frame: Day 1 (Pre-dose), Day 29 and then every 8 weeks until disease progression or discontinuation from study or up to 152 weeks
| Milestone | Axitinib |
|---|---|
| Started | 62 |
| Completed | 0 |
| Not completed | 62 |
| Withdrew: Lack of efficacy | 30 |
| Withdrew: Adverse event | 22 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Other | 8 |
| Withdrew: Ongoing | 1 |
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of responses. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.
| Percentage of Participants | Axitinib |
|---|---|
| Percentage of Participants With Objective Response (OR) | 22.6 (12.9 to 35.0) |
Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
| Days | Axitinib |
|---|---|
| Progression-free Survival (PFS) | 225 (203 to 334) |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| Days | Axitinib |
|---|---|
| Duration of Response (DR) | 531 (225 to NA) |
Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.
| Days | Axitinib |
|---|---|
| Overall Survival (OS) | 412.5 (256.0 to 570.0) |
FKSI-DRS is a subset of FKSI which is a questionnaire for FACT -Kidney Symptom Index used to assess Quality of Life (QoL)/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions and the FKSI-DRS consisted of 9 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI-DRS ranged between 0-36. Since the questions could be reversed coded, as appropriate, before calculating FKSI-DRS, 0 and 36 could be considered the worst and best health states based on the 9 questions comprising FKSI-DRS.
| Units on a Scale | Axitinib |
|---|---|
| Baseline (n=62) | 28.94 (27.69 to 30.19) |
| Day 1 (Cycle 2) (n=52) | 27.12 (25.76 to 28.47) |
| Day 1 (Cycle 3) (n=46) | 27.11 (25.79 to 28.43) |
| Day 1 (Cycle 4) (n=41) | 27.68 (26.21 to 29.16) |
| Day 1 (Cycle 5) (n=39) | 27.94 (26.55 to 29.34) |
| Day 1 (Cycle 6) (n=33) | 27.31 (25.52 to 29.11) |
| Day 1 (Cycle 7) (n=32) | 28.56 (26.79 to 30.33) |
| Day 1 (Cycle 8) (n=30) | 28.55 (26.58 to 30.53) |
| Day 1 (Cycle 9) (n=27) | 28.75 (27.05 to 30.44) |
| Day 1 (Cycle 10) (n=19) | 29.37 (27.40 to 31.34) |
| Day 1 (Cycle 11) (n=17) | 29.35 (27.13 to 31.57) |
| Day 1 (Cycle 12) (n=17) | 29.24 (26.67 to 31.80) |
| Day 1 (Cycle 13) (n=16) | 30.41 (28.27 to 32.56) |
| Day 1 (Cycle 14) (n=15) | 31.02 (29.56 to 32.47) |
| Day 1 (Cycle 15) (n=14) | 30.29 (28.48 to 32.09) |
| Day 1 (Cycle 16) (n=14) | 30.79 (28.88 to 32.70) |
| Day 1 (Cycle 17) (n=13) | 31.46 (29.10 to 33.82) |
| Day 1 (Cycle 18) (n=12) | 31.08 (29.20 to 32.97) |
| Day 1 (Cycle 19) (n=9) | 29.44 (26.72 to 32.17) |
| Day 1 (Cycle 20) (n=10) | 29.80 (27.87 to 31.73) |
| Day 1 (Cycle 21) (n=11) | 29.91 (26.71 to 33.11) |
| Day 1 (Cycle 22) (n=10) | 30.80 (27.88 to 33.72) |
| Day 1 (Cycle 23) (n=9) | 30.22 (25.74 to 34.70) |
| Day 1 (Cycle 24) (n=8) | 31.75 (28.76 to 34.74) |
| Day 1 (Cycle 25) (n=7) | 31.14 (27.58 to 34.70) |
| Day 1 (Cycle 26) (n=7) | 31.29 (27.76 to 34.82) |
| Day 1 (Cycle 27) (n=7) | 32.00 (28.08 to 35.92) |
| Day 1 (Cycle 28) (n=5) | 34.00 (31.37 to 36.63) |
| Day 1 (Cycle 29) (n=6) | 33.83 (31.49 to 36.17) |
| Day 1 (Cycle 30) (n=6) | 34.00 (30.82 to 37.18) |
| Day 1 (Cycle 31) (n=4) | 33.75 (28.49 to 39.01) |
| Day 1 (Cycle 32) (n=1) | 34.00 (NA to NA) |
| Day 1 (Cycle 33) (n=1) | 34.00 (NA to NA) |
| Day 1 (Cycle 34) (n=0) | NA (NA to NA) |
| Day 1 (Cycle 35) (n=1) | 33.00 (NA to NA) |
| Day 1 (Cycle 36) (n=1) | 33.00 (NA to NA) |
| Day 1 (Cycle 37) (n=1) | 29.00 (NA to NA) |
| Day 1 (Cycle 38) (n=1) | 30.00 (NA to NA) |
| at Follow Up (n=9) | 25.11 (20.64 to 29.58) |
Data for this outcome measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms.
| Units on a Scale | Axitinib |
|---|---|
| Baseline (n=62) | 44.84 (42.65 to 47.03) |
| Day 1 (Cycle 2) (n=52) | 41.40 (39.13 to 43.67) |
| Day 1 (Cycle 3) (n=46) | 41.62 (39.28 to 43.97) |
| Day 1 (Cycle 4) (n=41) | 42.26 (39.55 to 44.97) |
| Day 1 (Cycle 5) (n=39) | 42.35 (39.85 to 44.84) |
| Day 1 (Cycle 6) (n=33) | 41.65 (38.82 to 44.49) |
| Day 1 (Cycle 7) (n=32) | 43.77 (41.09 to 46.45) |
| Day 1 (Cycle 8) (n=30) | 44.00 (40.75 to 47.25) |
| Day 1 (Cycle 9) (n=27) | 44.80 (41.84 to 47.76) |
| Day 1 (Cycle 10) (n=19) | 45.39 (41.82 to 48.95) |
| Day 1 (Cycle 11) (n=17) | 44.14 (40.23 to 48.06) |
| Day 1 (Cycle 12) (n=17) | 44.73 (40.79 to 48.67) |
| Day 1 (Cycle 13) (n=16) | 46.13 (42.19 to 50.06) |
| Day 1 (Cycle 14) (n=15) | 47.04 (43.94 to 50.14) |
| Day 1 (Cycle 15) (n=14) | 45.93 (42.67 to 49.20) |
| Day 1 (Cycle 16) (n=14) | 46.16 (41.96 to 50.36) |
| Day 1 (Cycle 17) (n=13) | 48.14 (44.18 to 52.10) |
| Day 1 (Cycle 18) (n=12) | 47.08 (42.43 to 51.72) |
| Day 1 (Cycle 19) (n=9) | 44.98 (39.24 to 50.71) |
| Day 1 (Cycle 20) (n=10) | 45.81 (41.41 to 50.20) |
| Day 1 (Cycle 21) (n=11) | 47.02 (40.99 to 53.05) |
| Day 1 (Cycle 22) (n=10) | 47.50 (42.06 to 52.94) |
| Day 1 (Cycle 23) (n=9) | 46.30 (38.77 to 53.83) |
| Day 1 (Cycle 24) (n=8) | 48.64 (42.38 to 54.91) |
| Day 1 (Cycle 25) (n=7) | 49.11 (44.46 to 53.77) |
| Day 1 (Cycle 26) (n=7) | 50.26 (45.32 to 55.19) |
| Day 1 (Cycle 27) (n=7) | 49.82 (43.61 to 56.02) |
| Day 1 (Cycle 28) (n=5) | 53.20 (46.55 to 59.85) |
| Day 1 (Cycle 29) (n=6) | 52.67 (45.84 to 59.49) |
| Day 1 (Cycle 30) (n=6) | 53.17 (46.26 to 60.08) |
| Day 1 (Cycle 31) (n=4) | 53.00 (40.74 to 65.26) |
| Day 1 (Cycle 32) (n=1) | 53.00 (NA to NA) |
| Day 1 (Cycle 33) (n=1) | 51.00 (NA to NA) |
| Day 1 (Cycle 34) (n=0) | NA (NA to NA) |
| Day 1 (Cycle 35) (n=1) | 51.00 (NA to NA) |
| Day 1 (Cycle 36) (n=1) | 51.00 (NA to NA) |
| Day 1 (Cycle 37) (n=1) | 45.00 (NA to NA) |
| Day 1 (Cycle 38) (n=1) | 48.00 (NA to NA) |
| At Follow Up (n=9) | 38.98 (32.46 to 45.49) |
AUCss: pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods, computed as each participant's average total daily dose (accounting for dose reductions and any recorded missed doses) divided by population estimated posthoc individual apparent clearance (CL/F), i.e., AUCss = Daily Dose/(CL/F), where F refers to the oral bioavailability, and CL refers to the systemic clearance. PR: responses with at least 30% decrease in sum of longest dimensions of target lesions using baseline (pre-treatment) sum of longest dimensions as reference. Logistic regression with general linear model was applied to data of PR using AUCss; PR was correlated with AUCss as fold increase in odds of PR with increase in AUCss. Fold increase was calculated as exponent of product of logistic regression slope coefficient and unit change of AUCss.
| Ratio | Axitinib |
|---|---|
| Fold change per 1 ng*hr/mL: Cycle1 | 1.0028 |
| Fold change per 100 ng*hr/mL: Cycle1 | 1.3300 |
AUCss is a pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods. PFS is median time from first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. Relationship of PFS versus AUCss was determined as median PFS in participants with high AUCss \[AUCss greater than or equal to (\>=) median AUCss\] or low AUCss \[AUCss less than (\<) median AUCss\].
| weeks | Axitinib |
|---|---|
| PFS at Low AUCss: Cycle1 (n=28) | 31 (24 to 80) |
| PFS at High AUCss: Cycle1 (n=29) | 39 (31 to NA) |
AUCss is a pharmacokinetic parameter derived from plasma concentration versus time data using non-compartmental or population based analysis methods. OS is time in weeks from the start of study treatment to date of death due to any cause. Relationship of OS versus AUCss was determined as median OS in participants with high AUCss \[AUCss \>= median AUCss\] or low AUCss \[AUCss \< median AUCss\].
| weeks | Axitinib |
|---|---|
| OS at Low AUCss: Cycle1 (n=28) | 43 (36 to 72) |
| OS at High AUCss: Cycle1 (n=29) | 88 (73 to NA) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib | — | 39/62 (62.9%) | 62/62 (100%) |
| Event | Axitinib |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/62 |
| DehydrationMetabolism and nutrition disorders | 6/62 |
| Abdominal painGastrointestinal disorders | 5/62 |
| HypotensionVascular disorders | 5/62 |
| NauseaGastrointestinal disorders | 4/62 |
| VomitingGastrointestinal disorders | 4/62 |
| Disease progressionGeneral disorders | 4/62 |
| HypertensionVascular disorders | 3/62 |
| Cardiac failure congestiveCardiac disorders | 2/62 |
| Myocardial ischaemiaCardiac disorders | 2/62 |
| Event | Axitinib |
|---|---|
| FatigueGeneral disorders | 47/62 |
| DiarrhoeaGastrointestinal disorders | 38/62 |
| Decreased appetiteMetabolism and nutrition disorders | 33/62 |
| NauseaGastrointestinal disorders | 27/62 |
| HypertensionVascular disorders | 26/62 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 23/62 |
| Mucosal inflammationGeneral disorders | 21/62 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 21/62 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 21/62 |
| VomitingGastrointestinal disorders | 19/62 |
| Age Continuous(Years) | Axitinib |
|---|---|
| Mean | 57.9 ± 9.4 |
| Sex: Female, Male(Participants) | Axitinib |
|---|---|
| Female | 20 |
| Male | 42 |
The record gives a start of Mar 2006, a primary completion of Feb 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 3 years 2 months after primary completion. A results delay was requested in May 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib